Status:
UNKNOWN
Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy
Lead Sponsor:
Unidad de Investigacion Medica en Enfermedades Renales
Conditions:
Chronic Kidney Diseases
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
PHASE3
Brief Summary
The increase in the prevalence of diabetes mellitus (DM) is one of the greatest public health challenges worldwide. Epidemiological studies have shown that DM is the leading cause of chronic kidney di...
Detailed Description
Aim: To evaluate the interaction between rs35652124 polymorphism and curcumin supplementation on the levels of NFE2L2 gene expression, antioxidant capacity and renal function in patients with early di...
Eligibility Criteria
Inclusion
- With T2DM according to the American Diabetes Association
- With any time of T2DM evolution
- With CKD stage 1-3a according to the K/DIGO guidelines
Exclusion
- Incomplete evaluations
- That they have not been attached to the assigned intervention with an established frequency of \<80%
- Decide to withdraw from the study
Key Trial Info
Start Date :
August 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2019
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT03262363
Start Date
August 1 2018
End Date
April 30 2019
Last Update
May 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Umae Hospital de Especialidades
Guadalajara, Jalisco, Mexico, 44340